Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…Effects of deep brain stimulation in the nucleus entopeduncularis on neuronal network activity after apomorphine-induced deficient sensorimotor gating in a rat model
Objective: Deficient sensorimotor gating induced by dopamine receptor agonists is used as an endophenotype for certain neuropsychiatric disorders, such as Tourette´s syndrome (TS), schizophrenia, and…A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease
Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…Sensor based gait analysis: Diagnostic application for apomorphine titration
Objective: The goal of the present study was to quantify individual gait changes by eGaIT during the standardized titration test for subcutaneous apomorphine treatment. Background:…Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine
Objective: The objetive of our study is to assess the utility of the subtypes IgG direct Coombs test (DCT) in maintenance apomorphine treatment without risk…Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)
Objective: Our aim was to establish whether objective measurements using the Parkinson's Kinetigraph can detect differences between patients undergoing different advanced therapy with either deep…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.